LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Centro Nacional de Investigaciones Oncológicas
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Oncológicas (48)
2023
-
Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer
Cancers, Vol. 15, Núm. 5
-
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Nature Reviews Clinical Oncology, Vol. 20, Núm. 3, pp. 143-159
-
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86
-
Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer
Cancers, Vol. 15, Núm. 23
-
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study
British Journal of Cancer, Vol. 128, Núm. 1, pp. 137-147
-
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Nature Communications, Vol. 14, Núm. 1
-
Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models
International Journal of Molecular Sciences, Vol. 24, Núm. 16
-
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222
2022
-
Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy
International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 163-192
-
Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy
Journal of Clinical Medicine, Vol. 11, Núm. 6
-
Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer
Expert Opinion on Emerging Drugs, Vol. 27, Núm. 3, pp. 289-300
-
Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 6, pp. 671-680
-
Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study
Lung Cancer, Vol. 167, pp. 41-48
-
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Nature medicine, Vol. 28, Núm. 4, pp. 752-765
-
Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapy
Nanoscale, Vol. 14, Núm. 22, pp. 8028-8040
-
YES1 Is a Druggable Oncogenic Target in SCLC
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403
2021
-
An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity
Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177
-
Identification of predictive biomarkers of response to hsp90 inhibitors in lung adenocarcinoma
International Journal of Molecular Sciences, Vol. 22, Núm. 5, pp. 1-18
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
-
Overview of virus and cancer relationships. Position paper
Revista Espanola de Quimioterapia, Vol. 34, Núm. 6, pp. 525-555